HALO - ハロザイム・セラピュ―ティクス (Halozyme Therapeutics Inc.) ハロザイム・セラピュ―ティクス

 HALOのチャート


 HALOの企業情報

symbol HALO
会社名 Halozyme Therapeutics Inc (ハロザイム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ハロザイム・セラピューティクス(Halozyme Therapeutics Inc.)は腫瘍学療法の開発と商業化を行うバイオ医薬品会社である。同社はヒトの酵素および他の候補薬剤の研究、開発、および商業化を行う。同社のセグメントには研究・開発活動およびHylenex組換え品の製品・販売を含む。同社の開発パイプラインは腫瘍学における臨床段階の製品候補を含む。リード腫瘍学プログラムはHAを蓄積する腫瘍の全身治療のために開発された分子実体であるPEGPH20(ポリエチレングリコール(PEG)イル化組換えヒトヒアルロニダーゼ)である。同社はステージIVの膵管腺癌(試験109-202および109-301)におけるPEGPH20の第II相および第III相臨床試験、非小細胞肺癌におけるフェーズIb臨床試験(試験107-201)、および非小細胞肺癌および胃癌におけるフェーズIb臨床試験(試験107-101)にある。   ハロザイム・セラピュ―ティクスは、米国のバイオ医薬品会社。細胞外マトリックスを変更するヒト酵素の研究に基づき、糖尿病、癌、皮膚病治療用の薬品を開発。同社の承認された製品や製品候補は、特許を取得した遺伝子組換え型ヒトヒアルロニダ―ゼ酵素「rHuPH20」をベ―スとしている。主要製品は、「Hylenex」「超高速インスリンプログラム」など。   
本社所在地 11388 Sorrento Valley Road San Diego CA 92121 USA
代表者氏名 Connie L. Matsui コニー・マツイ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-794-8889
設立年月日 1998年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 255人
url www.halozyme.com
nasdaq_url https://www.nasdaq.com/symbol/halo
adr_tso
EBITDA EBITDA(百万ドル) 92.39600
終値(lastsale) 17.53
時価総額(marketcap) 2529653327.2
時価総額 時価総額(百万ドル) 2360.817
売上高 売上高(百万ドル) 319.36900
企業価値(EV) 企業価値(EV)(百万ドル) 2127.968
当期純利益 当期純利益(百万ドル) 76.27700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Halozyme Therapeutics Inc. revenues increased 4% to $66.1M. Net loss decreased 21% to $50.4M. Revenues reflect Royalties increase of 43% to $40.9M Revenues under collaborative agreements increase of 33% to $13.9M. Lower net loss reflects Investment and other income increase from $722K to $3.7M (income) Interest expense decrease of 9% to $10M (expense).

 HALOのテクニカル分析


 HALOのニュース

   Let's Take Another Look at Halozyme Therapeutics  2021/03/04 17:05:00 The Street RealMoney
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead….HALO
   Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027  2021/02/25 03:41:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027…
   Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027  2021/02/23 21:10:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate…
   Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results  2021/02/23 21:01:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and outlook. "The fourth quarter capped an…
   Halozyme Therapeutics's Earnings: A Preview  2021/02/22 10:07:00 Benzinga
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential …
   Let's Take Another Look at Halozyme Therapeutics  2021/03/04 17:05:00 The Street RealMoney
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead….HALO
   Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027  2021/02/25 03:41:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027…
   Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027  2021/02/23 21:10:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate…
   Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results  2021/02/23 21:01:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and outlook. "The fourth quarter capped an…
   Halozyme Therapeutics's Earnings: A Preview  2021/02/22 10:07:00 Benzinga
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential …
   Let's Take Another Look at Halozyme Therapeutics  2021/03/04 17:05:00 The Street RealMoney
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead….HALO
   Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027  2021/02/25 03:41:00 PR Newswire
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027…
   Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027  2021/02/23 21:10:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate…
   Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results  2021/02/23 21:01:00 PR Newswire
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and outlook. "The fourth quarter capped an…
   Halozyme Therapeutics's Earnings: A Preview  2021/02/22 10:07:00 Benzinga
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ハロザイム・セラピュ―ティクス HALO Halozyme Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)